Tamoxifen, raloxifene, and the prevention of breast cancer

Endocr Rev. 1999 Jun;20(3):253-78. doi: 10.1210/edrv.20.3.0368.

Authors

V C Jordan¹, M Morrow

Affiliation

¹ Department of Molecular Pharmacology, Biological Chemistry, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA.

PMID: 10368771
DOI: 10.1210/edrv.20.3.0368

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anticarcinogenic Agents / pharmacology
Anticarcinogenic Agents / therapeutic use*
Breast Neoplasms / drug therapy
Breast Neoplasms / prevention & control*
Clinical Trials as Topic
Estrogen Antagonists / pharmacology
Estrogen Antagonists / therapeutic use
Female
Humans
Piperidines / pharmacology
Piperidines / therapeutic use*
Raloxifene Hydrochloride
Receptors, Estrogen / antagonists & inhibitors
Receptors, Estrogen / physiology
Risk Factors
Tamoxifen / pharmacology
Tamoxifen / therapeutic use*

Substances

Anticarcinogenic Agents
Estrogen Antagonists
Piperidines
Receptors, Estrogen
Tamoxifen
Raloxifene Hydrochloride